Skip to main content
. 2018 Jun 1;9(42):26605–26615. doi: 10.18632/oncotarget.24902

Figure 2. Flow cytometry assessments of the aptamer's binding to CD19 protein, BSA, or OVA.

Figure 2

(A) Beads coated with CD19 protein was treated with FITC-labeled aptamer. (B) BSA beads treated with FITC-labeled aptamer. (C) OVA beads treated with FITC-labeled aptamer. Black curves represent the control fluorescence signals generated by FITC-labeled random DNA from the library pool. Red curves are signals produced by aptamer LC1.